secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001193125-24-024761
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma details royalties and funding from Novartis acquisition of MorphoSys at €68/share
--------------------------------------------------------------------------------

- Royalty Pharma holds 3% royalty on pelabresib (myelofibrosis) and tulmimetostat (EZH2 inhibitor) future sales; NDA submission expected mid-2024.
- Tiered mid-single digit royalty on Tremfya (J&J; $3.1B sales FY2023) and 3.3%-4.2% effective royalty on Roche's trontinemab for Alzheimer's.
- MorphoSys to make 36 payments totaling ~$660M (2.2x funded $300M) to repay Development Funding Bonds, starting Q4 2024.
- Royalty Pharma's 1,337,552 MorphoSys shares valued at ~$100M at proposed Novartis acquisition price.
- Royalty Pharma had committed up to $2.025B funding to MorphoSys in July 2021 strategic partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524024761/0001193125-24-024761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524024761/d105575d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-024761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer